BCR/ABL融合基因阳性的急性淋巴细胞白血病的细胞形态与免疫表型特点  

Morphological and Immunophenotypic features of BCR/ABL Fusion gene positive in Acute Lymphoblast Leukemia

作　　者：程静[1] 陈少谦 江晓冰[1] 吴珊慧 刘敏[1] 

机构地区：[1]中山大学附属第一医院检验科,广州市510180

出　　处：《实用医学杂志》2016年第24期4125-4128,共4页The Journal of Practical Medicine

摘　　要：目的:研究BCR/ABL融合基因阳性急性淋巴细胞白血病(BCR/ABL+ALL)的细胞形态和免疫表型特点,并探讨其在预测疾病预后和指导临床治疗中的价值。方法:对BCR/ABL融合基因阳性的37例ALL患者(除外CML急淋变患者)和阴性的50例ALL患者骨髓细胞形态和免疫表型特征进行回顾性分析。结果:所有病例均表达CD19和CD79a,BCR/ABL融合基因阳性与BCR/ABL融合基因阴性ALL表面分子表达有统计学差异(P<0.05)的包括CD34(97.3%与80.0%),CD33(41.7%与16.3%),CD10(100.0%与86.0%),CD20(70.3%与30.0%)及CD56(28.6%与53.1%)。BCR/ABL融合基因阳性与BCR/ABL融合基因阴性ALL患者骨髓涂片检查细胞形态差异无统计学意义。结论:BCR/ABL融合基因阳性的ALL可能存在较为特征性的免疫表型,通过检测这些特征性免疫表型将有助于临床对ALL疾病进展迅速、预后差的亚型患者进行预测,并指导临床个体化治疗。Objective To explore the morphological feature and the immunophenotypic characteristics of BCR/ABL fusion gene positive in acute lymphoblastic leukemia （ALL） and to evaluate their significance in predicting prognosis and guiding clinical treatment. Methods The morphological features and immunophenotypic heterogeneity were studied retrospectively in 37 ALL patients with positive BCR/ABL fusion gene and 50 ALL patients with BCR/ABL fusion gene negative. Results BCR/ABL positive and BCR/ABL negative ALL patients with bone marrow smear examination showed no significant difference in cell morphology. All of the ALL patients were positive for CD19 and CD79a, There was significant difference in expression of CD34 （97.3% vs 80%）, CD10（96.2% vs 71.8%）, CD33（41.7% vs 16.3%）,CD10（100% vs 86%）, CD20（70.3% vs 30%） and CD56 （28.6% vs 53.1% ） between BCR/ABL positive and negative groups. Conclusion There may be more characteristic of the immune phenotype in BCR/ABL positive ALL. It is helpful for predicting the poor outcome of the disease,and for defining patients who require different treatment strategies by detecting these immune phenotype.

关 键 词：急性淋巴细胞白血病 BCR/ABL融合基因 免疫表型 细胞形态学 

分 类 号：R733.71[医药卫生—肿瘤]